AUTISM SPECTRUM DISORDER: A POSSIBLE LINK WITH CHONDROITIN SULFATE

INTRODUCTION

Autism spectrum disorder (ASD) are characterized by a lack of social interaction and impaired verbal and non-verbal communication and can be diagnosed as early as three years of age (Park et al., 2016).

Over the last two decades, ASD diagnoses have steadily increased (Fisch, 2012). Some specialists have argued that this increase has been due to an expansion of the diagnostic criteria and increased social awareness; however, newly diagnosed patients appear to have similar profiles as those diagnosed using previous assessments, and the new criteria do not seem to have influenced these results (Baio et al., 2018; Graf, Miller, Epstein, & Rapin, 2017). The diagnosis of ASD is observational and based on the patient’s behavior, although some biomarkers have been proposed (Galiana-Simal, Munoz-Martinez, Calero-Bueno, Vela-Romero, & Beato-Fernandez, 2018).

Glycosaminoglycans (GAGs) are complex polysaccharides, composed of repeating disaccharide units. The composition of these units and their linking patterns result in the formation of distinct GAGs, such as chondroitin sulfate (CS), dermatan sulfate (DS) and heparan sulfate (HS) (Gandhi & Mancera, 2008). GAGs may conjugate with proteins, known as proteoglycans, and are essential for embryogenesis and neuronal migration during development. CS proteoglycan mutations may be associated with schizophrenia and bipolar disorder (Couchman, 2010; Iozzo & Schaefer, 2015; Maeda, 2015; Muhleisen et al., 2012; Nakato & Li, 2016; Turner & Grose, 2010). Additionally, excreted GAGs in the urine may be used to diagnose mucopolysaccharidoses (MPS) (Coutinho, Lacerda, & Alves, 2012). Recently, the genes associated with glycan synthesis have been thought to play a role in the development of ASD (Dwyer & Esko, 2016; Endreffy, Bjorklund, Dicso, Urbina, & Endreffy, 2016). Therefore, this study aimed to assess whether the concentrations of GAGs in the urine of ASD patients can be used to facilitate the diagnosis of ASD, potentially resulting in a better understanding of the ASD pathophysiology and possible therapeutic targets.

METHODS

RESULTS

This study included 12 participants, nine who were diagnosed with ASD and three HVs. One ASD patient was excluded based on the ROUT’s test results for the ABC scores, and one HV was excluded due to sample deterioration. The sample descriptors are summarized in Table 1.

Our data revealed that the ABC scores for the ASD patients (63.5 ± 23.4) were significantly higher than those for the HVs (5.0 ± 2.8), as shown in Figure 1B. The ABC sub-scores revealed that ASD patients received higher scores for all investigated parameters, except for the relationship (RE) category (Figure 1B). The gel electrophoresis for the assessment of GAG concentrations in the urine showed the prevalence of CS, small signs of HS and none DS (Figure 1A) A significant reduction (p = 0.04) of 46.1% in the CS concentrations was observed in the urine of ASD patients compared with the urine of HV patients. Whereas ASD patients had a mean CS concentration of 9.44 ± 5.75 mg/L, HVs had a considerably higher mean concentration of 17.51 ± 4.04 mg/L (Figure 1C).

• Download figure
• Open in new tab

Figure 1. Discrepancies in the CS concentrations in the urine between ASD patients and HVs.

(A) Processed urine samples were analyzed for GAG concentrations using an electrophoretic method, in which CS was prevalent. S1 and S2 are the CS/DS/HS standards, A1 – A9 (except A7 which was excluded) are ASD patients, and C2 and C3 are HVs. (B) ASD patients displayed significantly higher ABC scores than HVs. All of the sub-scores, except for relationship (RE), were higher in ASD patients than in HVs. The horizontal dotted line at y = 49 indicates the scale cut-off. Other sub-scores abbreviations: sensory stimulus (SS), use of body and objects (BO), language (LG), and personal-social development (PS). (C) The measured CS concentration in the urine of ASD patients is significantly lower than that in HVs. (D) A negative correlation between ABC scores and CS concentration in urine, based on the Spearman’s ρ.

Although a larger sample size would be necessary to estimate a precise correlation between the two examined variables (i.e., ABC score vs. CS concentration in urine), we observe that ABC scores for ASD patients were negatively correlated (Spearman’s ρ = –0.2635) with the measured GAG concentrations in the urine, which could indicate that lower levels of CS in the urine may be associated with worse ASD clinical diagnoses.

DISCUSSION

As previously mentioned, GAGs have been used to monitor MPS. During these pathologies, CS, DS, HS or keratan sulfate (KS) can be observed in patient urine samples, depending on the MPS (Coutinho et al., 2012). However, we discovered that ASD patients display lower urinary CS concentrations for reasons that remain unknown.

There is no corroborating evidence in the literature that would explain the lower CS concentrations observed in the urine samples from ASD patients. The deletion of EXT1, GPC5, GPC6, and mutation of HS3ST5 and SGSH, appear to be associated with ASD (Dwyer & Esko, 2016). These genes participate in HS synthesis, sulfation, degradation, or HS proteoglycan synthesis. In addition, the deletion of B3GALT6, a gene that affects both HS and CS synthesis, also appears to be implicated with ASD (van der Zwaag et al., 2009).

The detection of GAGs in the urine may not be appropriate for the detection of HS in these samples, as this GAGs was hardly detectable either in patients with ASD or HVs urines; however, because the glycan balance may be altered in patients with ASD, these alterations can be verified based on the CS concentrations, which revealed significant discrepancies in this pilot study. A larger sample may establish whether urinary CS concentrations can be utilized as a biomarker for ASD and help shed light on the still unknown ASD pathophysiology, and this is a clear limitation of this study. In addition, more studies with HS or specific proteoglycans in the blood or other samples may also increase our understanding of ASD pathophysiology.

In this pilot study, we were able to infer that ASD patients may excrete less CS in the urine, which can be assessed using a fast and low-cost analytical method.